Point of care molecular and antigen detection tests for COVID-19: current status and future prospects

References

• Khandker SS, Hashim NHH, Deris ZZ, et al. Diagnostic Accuracy of Rapid Antigen Test Kits for Detecting SARS-CoV-2: A Systematic Review and Meta-Analysis of 17,171 Suspected COVID-19 Patients. J Clin Med. 2021;10(16):3493. DOI:10.3390/jcm10163493.
   PubMed Web of Science ®Google Scholar
• Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581(7809):465–469.
   PubMed Web of Science ®Google Scholar
• FDA Office of the Commissioner. Coronavirus (COVID-19) Update: FDA informs public about possible accuracy concerns with Abbott ID NOW Point-of-Care Test. FDA 2020. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-informs-public-about-possible-accuracy-concerns-abbott-id-now-point (Cited 2021 May 11).
   Google Scholar
• Stokes W, Berenger BM, Singh T, et al. Acceptable performance of the Abbott ID NOW among symptomatic individuals with confirmed COVID-19. J Med Microbiol. 2021;70(7):001372.
   Web of Science ®Google Scholar
• Thwe PM, Maiyo E, Ren P. Abbott ID now COVID-19 assay performance: a year in review. Diagn Microbiol Infect Dis. 2021;101(4):115536.
   PubMed Web of Science ®Google Scholar
• Stokes W, Venner AA, Buss E, et al. Then and NOW: a prospective population-level validation of the abbott ID NOW SARS-CoV-2 Device implemented in multiple settings for testing asymptomatic and symptomatic individuals. MedRxiv. 2022 .March.30; 22274189. • This was a large validation comparing performance of the Abbott ID Now with laboratory RT PCR. The authors studied performance in a variety of patient populations/settings and looked at performance in both symptomatic and asymptomatic individuals
   Google Scholar
• Y-P T, Iqbal J, O’Leary T. Sensitivity of ID NOW and RT–PCR for detection of SARS-CoV-2 in an ambulatory population. ELife. 2021;10:e65726.
   PubMed Web of Science ®Google Scholar
• Graham M, Muhi S, Hoang T, et al. Multi-site point of care assessment of Abbott ID NOW rapid molecular test for SARS-CoV-2 in a low-prevalence setting. Pathol. 2021;53:912–914.
   PubMed Web of Science ®Google Scholar
• Goupil-Sormany I, Longtin J, Dumaresq J, et al. The PRONTO study: clinical performance of ID NOW in individuals with compatible SARS-CoV-2 symptoms in walk-in centres—accelerated turnaround time for contact tracing. Canada Communicable Disease Report. 2021;47(12):534–542.
   PubMedGoogle Scholar
• Tsang HF, Leung WMS, Chan LWC, et al. Performance comparison of the Cobas® Liat® and Cepheid® GeneXpert® systems on SARS-CoV-2 detection in nasopharyngeal swab and posterior oropharyngeal saliva. Expert Rev Mol Diagn. 2021;21(5):515–518.
   PubMed Web of Science ®Google Scholar
• Mahmoud SA, Ganesan S, Ibrahim E, et al. Evaluation of six different rapid methods for nucleic acid detection of SARS-COV-2 virus. J Med Virol. 2021;93(9):5538–5543.
   PubMed Web of Science ®Google Scholar
• Hansen G, Marino J, Wang Z-X, et al. Clinical performance of the point-of-care cobas liat for detection of SARS-CoV-2 in 20 minutes: a multicenter study. J Clin Microbiol. 2021;59(2):e02811–20.
   PubMed Web of Science ®Google Scholar
• T-K E, Chou Y-C, Chen S-Y, et al. Rapid Cobas Liat SARS-CoV-2 assay in comparison with the laboratory-developed real-time RT-PCR Test. Clin Lab. 2021;67(11).
   Web of Science ®Google Scholar
• Daum LT, Fischer GW. Rapid and safe detection of SARS-CoV-2 and influenza virus RNA using onsite quantitative PCR diagnostic testing from clinical specimens collected in molecular transport medium. J Appl Lab Med. 2021;6(6):1409–1416.
   PubMedGoogle Scholar
• Blackall D, Moreno R, Plotinsky R, et al. Performance characteristics of the roche diagnostics cobas Liat PCR system as a COVID-19 screening tool for hospital admissions in a regional health care delivery system. J Clin Microbiol. 2021;59(10):e0127821.
   PubMed Web of Science ®Google Scholar
• Beaumont J, Nargesi MM, Smith S, et al. Sensitivity and potential utility of SARS-CoV-2 rapid antigen and nucleic acid amplification tests in the context of an elimination approach. N Z Med J. 2021;134(1546):28–37.
   PubMed Web of Science ®Google Scholar
• US FDA. Potential for False Results with Roche Molecular Systems, Inc. cobas SARS-CoV-2 & Influenza Test for use on cobas Liat System-Letter to Clinical Laboratory Staff, Point-of-Care Facility Staff, and Health Care Providers 2021. https://www.fda.gov/medical-devices/letters-health-care-providers/potential-false-results-roche-molecular-systems-inc-cobas-sars-cov-2-influenza-test-use-cobas-liat. Cited 2022 January 20
   Google Scholar
• Cue Health. CueTM COVID-19 Test Instructions For Use 2021. Available at: https://www.fda.gov/media/138826/download. Cited 2022 January 20
   Google Scholar
• Donato LJ, Trivedi VA, Stransky AM, et al. Evaluation of the Cue Health point-of-care COVID-19 (SARS-CoV-2 nucleic acid amplification) test at a community drive through collection center. Diagn Microbiol Infect Dis. 2021;100(1):115307.
   PubMed Web of Science ®Google Scholar
• Lucira Health. Lucira TM Checkit COVID-19 test kit instructions for use. Available from: https://www.ncbi.nlm.nih.gov/books/NBK572322/bin/fdacovideuas_147494.pdf. Cited 2022 January 20
   Google Scholar
• Araf Y, Akter F, Tang YD, et al., Omicron variant of SARS-CoV-2: genomics, transmissibility, and responses to current COVID-19 vaccines. J Med Virol. 2022;95(5):1825–1832.
   Google Scholar
• Stokes W, Venner AA, Buss E, et al. Evaluation of the ID NOW among symptomatic individuals during the omicron wave. Medrxiv. 22275316. 2022 May 19.
   Google Scholar
• Marais G, Hsiao N, Iranzadeh A, et al. Saliva swabs are the preferred sample for Omicron detection. Medrxiv. 21268. 2021 December 22.
   Google Scholar
• Che XY, Has W, Wang Y, et al. Nucleocapsid protein as early diagnostic marker for SARS. Emerg Infect Dis. 2004;10(11):1947–1949.
   PubMed Web of Science ®Google Scholar
• Boikova D, Klann K, Koch B, et al. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. Nature. 2020;583(7816):469–472.
   PubMed Web of Science ®Google Scholar
• Rota PA, Oberste MS, Monroe SS, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science. 2003;300(5624):1394–1399.
   PubMed Web of Science ®Google Scholar
• WHO Interim guidance: antigen-detection in the diagnosis of SARS-CoV-2 infection. Published 2021 Oct 6. https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-2infection-using-rapid-immunoassays
   Google Scholar
• Albert E, Torres I, Bueno F, et al. Field evaluation of a rapid antigen test (Panbio COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres. Clin Microbiol Infect. 2020;27(3):e7–10.
   Web of Science ®Google Scholar
• Mina MJ, Parker R, Larremore DB. Rethinking COVID-19 test sensitivity - a strategy for containment. N Engl J Med. 2020;383(22):e120.
   PubMed Web of Science ®Google Scholar
• Salvatore PP, Shah MM, Ford L, et al. Quantitative comparison of SARS-CoV-2 nucleic acid amplification test and antigen testing algorithms: a decision analysis simulation model. BMC Public Health. 2022;22(82). DOI:10.1186/s12889-021-12489-8.
   PubMedGoogle Scholar
• Killingley B, Mann A, Kalinova M, et al. Preprint at research square 10.21203/rs.3.rs-1121993/v1 (2022).
   Google Scholar
• Kucirka LM, Lauer SA, Laevendecker O, et al. Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure. Ann Intern Med. 2020;173(4):262–267.
   PubMed Web of Science ®Google Scholar
• Stokes W, Berenger BM, Scott B, et al. One Swab Sits All: performance of a Rapid, Antigen-Based SARS-CoV-2 test using a nasal swab, nasopharyngeal swab for nasal collection, and RT-PCR confirmation from residual extraction buffer. J Appl Lab Med. 2022;7(4):834–841. In press.
   PubMedGoogle Scholar
• Stokes W, Berenget BM, Portnov D, et al. Clinical performance of the Abbott Panbio with nasopharyngeal, throat, and saliva swabs among symptomatic individuals with COVID-19. Our J Clin Microbiol Infec Dis. 2021;40(8):1721–1726.
   PubMed Web of Science ®Google Scholar
• Schrom J, Marquez C, Pilarowski G, et al. Direct comparison of SARS-CoV-2 Nasal RT-PCR and rapid antigen test (BinaxNOW™) at a community testing site during an omicron surge. MedRxiv. 22268954. 2022 January 08.
   Google Scholar
• Lindner AK, Nikolai O, Kausch F, et al. Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal swab versus professional-collected nasopharyngeal swab. Eur Respir J. 2021;57(4):2003961.
   PubMed Web of Science ®Google Scholar
• Cockerill FR, Wohlgemuth JG, Radcliff J, et al. Evolution of specimen self-collection in the COVID-19 Era: implications for population health management of infectious diseases. Popul Health Manag. 2021;24(Suppl 1):S26–34.
   PubMedGoogle Scholar
• Stohr JJJM, Zwart VF, Goderski G, et al. Self-testing for the Detection of SARS-CoV-2 infection with rapid antigen tests for people with suspected COVID-19 in the community. Clin Microbiol Infect. 2021;28(5):695–700. In press.
   PubMed Web of Science ®Google Scholar
• Tonen-Wolyec S, Dupont R, Awaida N, et al. Evaluation of the practicability of biosynex antigen self-test COVID-19 AG+ for the Detection of SARS-CoV-2 nucleocapsid protein from self-collected nasal mid-turbinate Secretions in the General Public in France. Diagnostics (Basel). 2021;11(12):2217.
   PubMedGoogle Scholar
• Yan A, Deslandes V, Sant N, et al. Self-collection and asymptomatic testing affect the positive predictive value of SARS-CoV-2 rapid antigen-detection tests. AMMI Canada CACMID Annual Conference. Abstract, accepted. (2022)
   Google Scholar
• Peeling RW, Olliaro PL, Boeras DI, et al. Scaling up COVID-19 rapid antigen tests: promises and challenges. Lancet Infect Dis. 2021;21(9):E290–5.
   PubMed Web of Science ®Google Scholar
• Kanji JN, Proctor DT, Stokes W, et al. Multicenter Post implementation assessment of the positive predictive value of SARS-CoV-2 antigen-based point-of-care tests used for screening of asymptomatic continuing care staff. J Clin Microbiol. 2021;59(11). DOI:10.1128/JCM.01411-21.
   Web of Science ®Google Scholar
• Potential for FP results with antigen tests for rapid detection of SARS-CoV-2. FDA Letter to Clinical Laboratory Staff and Healthcare providers, 2020
   Google Scholar
• Government of Canada interim guidance on the use of rapid antigen detection test for the identification of SARS-CoV-2, 2020
   Google Scholar
• Shaw JLV, Deslandes V, Smith J, et al. Evaluation of the Abbott Panbio TM COVID-19 Ag rapid antigen test for the detection of SARS-CoV-2 in asymptomatic Canadians. Diagn Microbiol Infec Dis. 2021;101(4):115514.
   PubMed Web of Science ®Google Scholar
• de Michelena P, Torres I, Ramos-Garcia A, et al. Real-life performance of a COVID-19 rapid antigen detection test targeting SARS-CoV-2 nucleoprotein for diagnosis of COVID-19 due to the Omicron variant. J Infect. 2022;84(5):E64–6.
   PubMed Web of Science ®Google Scholar
• Deerain J, Druce J, Tran T, et al. Assessment of the analytical sensitivity of ten lateral flow devices against SARS-CoV-2 Omicron variant. J Clin Micro. 2022;60(2):e0247921.
   PubMed Web of Science ®Google Scholar
• Berkliz M, Perez-Rodriguez F, Puhach O, et al. Sensitivity of SARS-CoV-2 antigen-detecting rapid tests for Omicron variant. MedRxiv. 2021 December 18.
   Google Scholar
• Oserman A, Badell I, Basara E, et al. Impaired detection of omicron by SARS-CoV-2 rapid antigen tests. Med Microbiol Immunol. 2022;211(2–3):105–117.
   PubMed Web of Science ®Google Scholar
• Yuan R, Aruffo E, Tan Y, et al. Projections of the transmission of the Omicron variant for Toronto, Ontario and Canada using surveillance data following recent changes in testing policies. Infect Dis Model. 2022;7(2):83–93.
   PubMedGoogle Scholar
• CDC Guidance for SARS-CoV-2 Rapid Testing Performed in Point-of-Care Settings, accessed Feb 2022
   Google Scholar
• Aziz H, Filkins A, Kwon YK. Review of COVID-19 Outcomes in Surgical Patients. Am Surg. 2020;86(7):741–745.
   PubMed Web of Science ®Google Scholar
• Deslandes V, Clark E, Thiruganasambandamoorthy V, et al. Implementation of the Abbott ID Now COVID-19 assay at a tertiary care center: a prospective pragmatic implementation study during the third wave of SARS-CoV-2 in Ontario. Diagn Microbiol Infectious Dis. 2022;102(3):115609.
   PubMed Web of Science ®Google Scholar
• Nguyen Van J-C, Gerlier C, Pilmis B, et al. Prospective evaluation of ID NOW COVID-19 assay used as point-of-care test in an emergency department. J Clin Virol. 2021;145:105021.
   PubMed Web of Science ®Google Scholar
• Meletis G, Gkeka I, Tychala A, et al. Laboratory evaluation of the Abbott ID NOW rapid severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) amplification assay and its potential use in the emergency department. Infect Control Hosp Epidemiol 2021 1–2 10.1017/ice.2021.360
   PubMedGoogle Scholar
• Babic N, Garner KS, Hirschhorn JW, et al. Evaluation of Abbott ID NOW COVID-19 POC test performance characteristics and integration in the regional health network workflows to improve health care delivery. Clin Biochem. 2021;In press. DOI:10.1016/j.clinbiochem.2021.12.003.
   PubMedGoogle Scholar
• Tworek JA, Khan F, Sekedat MD, et al. The utility of rapid nucleic acid amplification testing to triage symptomatic patients and to screen asymptomatic preprocedure patients for SARS-CoV-2. Open Forum Infect Dis. 2021;8(1). DOI:10.1093/ofid/ofaa607.
   PubMed Web of Science ®Google Scholar
• Gerlier C, Pilmis B, Ganansia O, et al. Clinical and operational impact of rapid point-of-care SARS-CoV-2 detection in an emergency department. Am J Emerg Med. 2021;50:713–718.
   PubMed Web of Science ®Google Scholar
• Soto M, Sampietro-Colom L, Vilella A, et al. Economic impact of a new rapid PCR assay for detecting influenza virus in an emergency department and hospitalized patients. PLoS One. 2016;11(1):e0146620.
   PubMed Web of Science ®Google Scholar
• Lee SM, Meyler P, Mozel M, et al. Provider attitudes and satisfaction with rapid preoperative point-of-care COVID-19 testing using ID NOWTM. Can J Anesth/J Can Anesth. 2021;68(11):1659–1667.
   PubMed Web of Science ®Google Scholar
• Mahase E. Covid-19: pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ. 2021;375(2713).
   Google Scholar
• Hodges E, Lefferts B, Bates E, et al. Use of rapid antigen testing for SARS-CoV-2 in remote communities — yukon-Kuskokwim Delta Region, Alaska, September 15, 2020–March 1, 2021. Morb Mortal Wkly Rep. 2021;70(33):1120–1123.
   PubMed Web of Science ®Google Scholar
• Fenollar F, Boyam A, Ballouche M, et al. Evaluation of the Panbio COVID-19 rapid antigen detection test device for the screening of patients with COVID-19. J Clin Microbiol. 2021;59(2):e02589–20.
   PubMed Web of Science ®Google Scholar
• Albert E, Torres I, Bueno F, et al. Field evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres. Clin Microbiol Infect. 2021;27(3):e7–e472.
   Web of Science ®Google Scholar
• Schuit E, Veldhuijzen IK, Venekamp RP, et al. Diagnostic accuracy of rapid antigen tests in asymptomatic and presymptomatic close contacts of individuals with confirmed SARS-CoV-2 infection: cross sectional study. BMJ. 2021;374(1676). DOI:10.1136/bmj.n1676.
   PubMedGoogle Scholar
• Pollock NR, Berlin D, Smole SC, et al. Implementation of SARS-CoV2 screening in k–12 schools using in-school pooled molecular testing and deconvolution by rapid antigen test. J Clin Microbiol. 2021;59(9):e0112321.
   PubMed Web of Science ®Google Scholar
• https://covid-19.ontario.ca/covid-19-test-and-testing-location-information
   Google Scholar
• Young BC, Eyre DW, Kendrick S, et al. Daily testing for contacts of individuals with SARS-CoV-2 infection and attendance and SARS-CoV-2 transmission in English secondary schools and colleges: an open-label, cluster-randomised trial. Lancet. 2021;398(10307):1217–1229.
   PubMed Web of Science ®Google Scholar
• Paltiel AD, Zheng A, Sax PE. Clinical and economic effects of widespread rapid testing to decrease SARS-CoV-2 transmission. Ann Intern Med. 2021;174(6):803–810.
   PubMed Web of Science ®Google Scholar
• Larremore DB, Wilderevan L, Lester E, et al. Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening. Sci Adv. 2021;7(1). DOI:10.1126/sciadv.abd5393.
   Web of Science ®Google Scholar
• Harmon K, de St Maurice A, Brady AC, et al. Surveillance Testing for SARS-CoV-2 infection in an asymptomatic athlete population: a prospective cohort study with 123,362 tests and 23,463 Paired RT-PCR/antigen samples. BMJ Open SEM. 2021;7(2):e001137.
   Web of Science ®Google Scholar
• Tande AJ, Binnicker MJ, Ting HH, et al. SARS-CoV-2 testing before international airline travel, december 2020 to may 2021. Mayo Clin Proc. 2021;96(11):2856–2860.
   PubMed Web of Science ®Google Scholar
• Rubin R, Tsang HF. The challenges of expanding rapid tests to curb COVID-19. JAMA. 2020;324(18):1813–1815.
   PubMed Web of Science ®Google Scholar
• Betsch C, Sprengholz P, Siegers R, et al. Empirical evidence to understand the human factor for effective rapid testing against SARS-CoV-2. PNAS. 2021;118(32):e2107179118.
   PubMed Web of Science ®Google Scholar
• CLSI. A quality management system model for laboratory services. In: CLSI guideline QMS01. 5th ed. Wayne: PA: Clinical and Laboratory Standards Institute; 2019.
   Google Scholar
• Nichols JH, Alter D, Chen Y, et al., AACC Guidance Document on Management of Point-of-Care Testing. J App Lab Med. 2020;5(4):762–787.
   PubMedGoogle Scholar
• Jacobs E, Kaplanis B, DeNigro J, et al. CLSI essential tools for implementation and management of a point of care testing program. 3rd. Wayne PA, USA: CLSI; 2016.
   Google Scholar
• Yip PM, Venner AA, Shea J, et al. Point-of-care testing: a position statement from the Canadian Society of Clinical Chemists. Clin Biochem. 2018;53:156–159.
   PubMed Web of Science ®Google Scholar
• Taher J, Randell EW, Arnoldo S, et al. Canadian Society of Clinical Chemists (CSCC) consensus guidance for testing, selection and quality management of SARS-CoV-2 point-of-care tests. Clin Biochem. 2021;95:1–12.
   PubMed Web of Science ®Google Scholar
• Bohn MK, Lippi G, Horvath AR, et al. IFCC interim guidelines on rapid point-of-care antigen testing for SARS-CoV-2 detection in asymptomatic and symptomatic individuals. Clin Chem Lab Med. 2021;59(9):1507–1515.
   PubMed Web of Science ®Google Scholar
• SARS-CoV-2 reference panel comparative data, 2021. US Food and Drug Administration.
   Google Scholar
• Hahn M, Olsen A, Stokes K, et al. Use, safety assessment, and implementation of two point-of-care tests for COVID-19 Testing. Am J Clin Path. 2021;156(3):370–380.
   PubMed Web of Science ®Google Scholar
• Public Health England. COVID-19: PHE laboratory assessments of inactivation methods [Internet]. GOV.UK. cited 2022 Jan 20]. Available from 2022 Jan 20: https://www.gov.uk/government/publications/covid-19-phe-laboratory-assessments-of-inactivation-methods. Cited 2022 January 20.
   Google Scholar
• Auerswald H, Yann S, Dul S, et al. Assessment of inactivation procedures for SARS-CoV-2. J Gen Virol. 2021;102(3):001539.
   Web of Science ®Google Scholar
• Hemati M, Soosanabadi M, Ghorashi T, et al. Thermal inactivation of COVID 19 specimens improves RNA quality and quantity. J Cell Physiol. 2021;236(7):4966–4971.
   PubMed Web of Science ®Google Scholar
• van Vockel D, Munier CML, Turville S, et al. Evaluation of commercially available viral transport medium (VTM) for SARS-CoV-2 inactivation and use in Point-of-Care (POC) testing. Viruses. 2020;12(11):1208.
   Web of Science ®Google Scholar
• Preliminary report from the Joint PHE Porton Down and University of Oxford SARS-CoV-2 test development and validation cell: POCT evaluation of lateral flow viral antigen detection devices (LFDs) for mass community testing (2020)
   Google Scholar
• Cormon VM, Hagge VC, Bleker T, et al. Comparison of seven commercial SARS-CoV-2 rapid point-of-care antigen tests: a single-centre laboratory evaluation study. Lancet Microbe. 2021;2(7):e311–19.
   PubMedGoogle Scholar
• Venner AA, Beach LA, Shea JL, et al. Quality assurance practices for point of care testing programs: recommendations by the Canadian society of clinical chemists point of care testing interest group. Clin Biochem. 2021;88:11–17.
   PubMed Web of Science ®Google Scholar
• Patriquin G, Davidson RJ, Hatchette TF, et al. Generation of false-positive SARS-CoV-2 antigen results with testing conditions outside manufacturer recommendations: a scientific approach to pandemic misinformation. Microbiol Spect. 2021;9(2):e00683.
   Web of Science ®Google Scholar
• Velavan TP, Galleria SR, Kremsner PG. How to (ab)use a COVID-19 antigen rapid test with soft drinks? Int J Infect Dis. 2021;111:28–30.
   PubMed Web of Science ®Google Scholar
• Kkw T, Sridhar S, Chiu KHY, et al. Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. Emerg Microbes Infec. 2021;10(1):507–535.
   PubMed Web of Science ®Google Scholar
• Zannoli S, Dirani G, Taddei F, et al. A deletion in the N gene may cause diagnostic escape in SARS-CoV-2 samples. Diagn Microbiol Infect Dis. 2022;02(1):115540.
   Google Scholar
• Sánchez-Calvo JM, Alados Arboledas JC, Ros V, et al. Diagnostic pre-screening method based on N-gene dropout or delay to increase feasibility of SARS-CoV-2 VOC B.1.1.7 detection. Diagn Microbiol Infect Dis. 2021;101(4):115491.
   PubMed Web of Science ®Google Scholar
• Krause E, Puyskens A, Bourquain D, et al. Sensitive on-site Detection of SARS-CoV-2 by ID NOW COVID-19. Mol Cell Probes. 2021;58(101742):101742.
   PubMedGoogle Scholar
• Jüni P, Baert S, Corbeil A, et al. Use of rapid antigen tests during the omicron wave. Science Briefs of the Ontario COVID-19 Science Advisory Table. 2022;56.
   Google Scholar
• Government of the United Kingdom.Target Product Profile: point of Care SARS-CoV-2 detection tests. December 29, 2021 update. Accessed online 2021 Feb 5: https://www.gov.uk/government/publications/how-tests-and-testing-kits-for-coronavirus-covid-19-work/target-product-profile-point-of-care-sars-cov-2-detection-tests#target-product-profile-point-of-care-sars-cov-2-detection-tests-1
   Google Scholar
• Adamson B, Sikka R, Wyllie AL, et al. Discordant SARS-CoV-2 PCR and rapid antigen test results when infectious: a december 2021 occupational case series. medRxiv. 2022 January 04;22268770.
   Google Scholar
• Goodall BL, LeBlank JL, Hatchette TF, et al. Investigating sensitivity of nasal or throat (ISNOT): a combination of both swabs increases sensitivity of SARS-CoV-2 rapid antigen tests. MedRxiv. 22269426. 2022 January 18.
   Google Scholar
• Berenger BM, Stokes W, Turnbull L, et al. Save the COVID-19 point-of-care nucleic acid test swab after testing to identify variants of concern. Clin Chem. 2021;68(1):249–251.
   PubMed Web of Science ®Google Scholar
• Land KJ, Boeras DI, Chen XS, et al. REASSURED diagnostics to inform disease control strategies, strengthen health systems and improve patient outcomes. Nat Microbiol. 2019;4(1):46–54.
   PubMed Web of Science ®Google Scholar
• Lim WY, Lan BL, Ramakrishnan N. Emerging biosensors to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a review. Biosensors (Basel). 2021;11(11):434.
   PubMedGoogle Scholar
• Rasmi Y, Li X, Khan J, et al. Emerging point-of-care biosensors for rapid diagnosis of COVID-19: current progress, challenges, and future prospects. Anal Bioanal Chem. 2021;413(16):4137–4159.
   PubMed Web of Science ®Google Scholar
• Fozouni P, Son S, Díaz de León Derby M, et al. Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy. Cell. 2021;184(2):323–333.
   PubMed Web of Science ®Google Scholar
• Cherkaoui D, Huang D, Miller BST, et al. Harnessing recombinase polymerase amplification for rapid multi-gene detection of SARS-CoV-2 in resource-limited settings. Biosens Bioelectron. 2021;189:113328.
   PubMed Web of Science ®Google Scholar
• Hu F, Liu Y, Zhao S, et al. A one-pot CRISPR/Cas13a-based contamination-free biosensor for low-cost and rapid nucleic acid diagnostics. Biosens Bioelectron. 2022;202:113994.
   PubMed Web of Science ®Google Scholar
• Otto CC, Kaplan SE, Stiles J, et al. Rapid molecular detection and differentiation of influenza viruses A and B. J Vis Exp. 2017;30;(119(1):54312.
   Google Scholar
• Green DA, St. George K, Kraft CS. Rapid antigen tests for influenza: rationale and significance of the FDA reclassification. J Clin Microbiol. 2018;56(10):e00711–8.
   PubMed Web of Science ®Google Scholar
• Chartrand C, Leeflang MMG, Minion J, et al. Accuracy of rapid influenza diagnostic tests. Ann Intern Med. 2012;156(7):500–511.
   PubMed Web of Science ®Google Scholar